SBIO
ETF / Mutual Fund
Nyse American
ALPS Medical Breakthroughs ETF
$30.32
-$2.71 (-8.22%)
Price Chart
Overview
About SBIO
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
AUM
Volume
663.9K
Avg. Volume
457.8K
Expense Ratio
0.60%
Fund Information
Exchange
Nyse American
Sector
Latest News for SBIO
Risk & Correlation Analysis
Market Correlation
1.15
Moderate Correlation
Volatility
Medium (0.29)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, SBIO shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
AUM
Volume663.9K
Expense Ratio0.60%
Important Dates
Next Dividend
Next Earnings
Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025